20+ Million Readerbase
Indexed In
  • Academic Keys
  • ResearchBible
  • CiteFactor
  • Access to Global Online Research in Agriculture (AGORA)
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • Euro Pub
  • Google Scholar
Share This Page
Recommended Webinars & Conferences
Journal Flyer
Flyer image

Editorial - (2015) Volume 4, Issue 2

Multiple Targeting Routes of MicroRNA-22 Inform Cancer Drug Discovery

Jianhua Xiong*
*Corresponding Author: Jianhua Xiong, Center for Molecular Medicine, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA, Tel: 727-767-8926 Email:

Abstract

MicroRNAs (miRNAs) are a class of ~23-nt endogenous noncoding RNA transcripts that mediate the posttranscriptional repression of target protein-coding genes . Although the first evidence for the role of miRNAs in cancer development was presented in 2002 , the clinical trials of miRNA-based cancer drugs is just burgeoning recently ]. Certain miRNA has been shown to be capable of targeting multiple mRNAs and affecting extensive protein output . Particularly, miRNA-22 (miR-22) is one of the most studied multitasking miRNAs in tumor initiation and progression to date and attracts special attention from basic and clinical research scientists.

Keywords: MicroRNAs,Cancer,Biomarker,leukemia,osteosarcoma

Editorial

MicroRNAs (miRNAs) are a class of ~23-nt endogenous non-coding RNA transcripts that mediate the posttranscriptional repression of target protein-coding genes [1]. Although the first evidence for the role of miRNAs in cancer development was presented in 2002 [2], the clinical trials of miRNA-based cancer drugs is just burgeoning recently [3]. Certain miRNA has been shown to be capable of targeting multiple mRNAs and affecting extensive protein output [4,5]. Particularly, miRNA-22 (miR-22) is one of the most studied multitasking miRNAs in tumor initiation and progression to date and attracts special attention from basic and clinical research scientists [6].

The first target estrogen receptor alpha (ERa) of miR-22 as a tumor suppressor was identified in breast cancer cells and clinical samples [7,8]. Subsequent studies reveal a series of oncogenic targets of miR-22 including HDAC4, SIRT1, p21, HIF-1a, EVI1, CDK6, EZR, Sp1, Wnt-1, TIAM1, MMP-2, MMP-9, CD151, CCNA2, PAPST1, KDM3A, BTG1, MTDH and CD147, MYCBP and MAX [6,9-19]. The expression of miR-22 could serve as a pivotal biomarker in tumor diagnosis and prognosis [6,20]. The tumor-suppressive function of miR-22 has been intensively investigated in various types of tumor cells and tissues including leukemia, lymphoma, endometrial endometrioid carcinoma, hepatoma, medulloblastoma, Ewing Sarcoma, and breast, lung, ovarian, colon, prostate, liver, gastric, cervical, colorectal and pancreatic cancer [6,9-19]. Of note, a regulatory loop involving miR-22 and robust oncogenic transcription factor c-Myc plays critical roles in breast tumorigenesis [18,19].

Contrary to the prevailing view of miR-22 as a tumor suppressor, the oncogenic effects of miR-22 has been characterized in leukemia, prostate cancer, cervical cancer,breast cancer, and bronchial epithelial cancer cells via PTEN signaling [6,21]. In addition, miR-22 can control cell stemness to promote hematopoietic transformation and breast cancer metastasis by directly targeting TET family members [22,23]. Upregulation of endogenous miR-22 expression can also cause impaired genomic integrity and DNA repair through inhibition of MDC1 in bone osteosarcoma cells [24]. Combined with these studies, cell stemness has been recently linked to low DNA damage implying the potential roles of miR-22 in coordinating cancer cell stemness and genomic stability [25,26]. Taken together, the opposing tumor suppressive and oncogenic activities of miR-22 may be two sides of the same coin, and they are both of critical importance in tumor cell homeostasis.

Owing to the advances in the miRNA-based therapeutics, chemically modified miRNA mimics and miRNA expression vectors hold great promise in tumor treatment and have already been in the clinical trials or developmental pipelines of pharmaceutical companies [6]. Although the cellular context is not a significant master of the majority of miRNA targets [27], it remains necessary to dissect the decisive factors for the multitasking of the evolutionarily conserved miR-22 [28]. Accumulating knowledge on the functional complexity and therapeutic safety will definitely improve the specificity and efficacy of miR-22-based tumor treatment. Previous studies in the quest to identify miR-22 functions have opened a new avenue for tumor treatment. Although there are numerous challenges to overcome for implementation of miRNA-based cancer therapy, it is expected that miR-22-based cancer drug will finally enter into clinical use and miRNA-associated treatment in patients with cancer will come of age.

Acknowledgements

The author is grateful to the National Institutes of Health (NIH) Fellows Editorial Board for editorial assistance.

References

  1. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
  2. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, et al. (2002) Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99: 15524-15529.
  3. Ling H, Fabbri M, Calin GA (2013) MicroRNAs and other non-coding RNAs as targets for anticancer drug development.Nat Rev Drug Discov 12: 847-865.
  4. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, et al. (2005) Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433: 769-773.
  5. Baek D, Villén J, Shin C, Camargo FD, Gygi SP, et al. (2008) The impact of microRNAs on protein output. Nature 455: 64-71.
  6. Xiong J (2012) Emerging roles of microRNA-22 in human disease and normal physiology. Curr Mol Med 12: 247-258.
  7. Pandey DP, Picard D (2009) miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA. Mol Cell Biol 29: 3783-3790.
  8. Xiong J, Yu D, Wei N, Fu H, Cai T, et al. (2010) An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples. FEBS J 277:1684-1694.
  9. Tang H, Kong Y, Guo J, Tang Y, Xie X, et al. (2013) Diallyl disulfide suppresses proliferation and induces apoptosis in human gastric cancer through Wnt-1 signaling pathway by up-regulation of miR-200b and miR-22. Cancer Lett 340:72-81
  10. Li B, Song Y, Liu TJ, Cui YB, Jiang Y, et al. (2013) miRNA-22 suppresses colon cancer cell migration and invasion by inhibiting the expression of T-cell lymphoma invasion and metastasis 1 and matrix metalloproteinases 2 and 9. Oncol Rep 29: 1932-1938.
  11. Li S, Hu R, Wang C, Guo F, Li X, et al. (2014) miR-22 inhibits proliferation and invasion in estrogen receptor α-positive endometrial endometrioid carcinomas cells. Mol Med Rep 9: 2393-2399.
  12. Wang X, Yu H, Lu X, Zhang P, Wang M, et al. (2014) MiR-22 suppresses the proliferation and invasion of gastric cancer cells by inhibiting CD151. Biochem Biophys Res Commun 445: 175-179.
  13. Yang F, Hu Y, Liu HX, Wan YJ (2015) MiR-22-silenced cyclin A expression in colon and liver cancer cells is regulated by bile acid receptor. J Biol Chem 290: 6507-6515.
  14. Xu QF, Pan YW, Li LC, Zhou Z, Huang QL, et al. (2014) MiR-22 is frequently downregulated in medulloblastomas and inhibits cell proliferation via the novel target PAPST1. Brain Pathol 24: 568-583.
  15. Parrish JK, Sechler M, Winn RA, Jedlicka P (2015) The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma.Oncogene 34: 257-262.
  16. Zhang H, Tang J, Li C, Kong J, Wang J, et al. (2015) MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells. Cancer Lett 356: 781-790.
  17. Tang Y, Liu X, Su B, Zhang Z, Zeng X, et al. (2015) microRNA-22 acts as a metastasis suppressor by targeting metadherin in gastric cancer. Mol Med Rep 11: 454-460.
  18. Xiong J, Du Q, Liang Z (2010) Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein. Oncogene 29: 4980-4988.
  19. Kong LM, Liao CG, Zhang Y, Xu J, Li Y, et al. (2014) A regulatory loop involving miR-22, Sp1, and c-Myc modulates CD147 expression in breast cancer invasion and metastasis. Cancer Res 74: 3764-3778.
  20. Wang W, Li F, Zhang Y, Tu Y, Yang Q, et al. (2013) Reduced expression of miR-22 in gastric cancer is related to clinicopathologic characteristics or patient prognosis. Diagn Pathol 8:102.
  21. Palacios F, Abreu C, Prieto D, Morande P, Ruiz S, et al. (2015) Activation of the PI3K/AKT pathway by microRNA-22 results in CLL B-cell proliferation. Leukemia 29:115-25.
  22. Song SJ, Ito K, Ala U, Kats L, Webster K, et al. (2013) The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell 13: 87-101.
  23. Song SJ, Poliseno L, Song MS, Ala U, Webster K, et al. (2013) MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 154: 311-324.
  24. Lee JH, Park SJ, Jeong SY, Kim MJ, Jun S, et al. (2015) MicroRNA-22 Suppresses DNA Repair and Promotes Genomic Instability through Targeting of MDC1. Cancer Res 75: 1298-1310.
  25. Xiong J (2014) SALL4: engine of cell stemness. Curr Gene Ther 14: 400-411.
  26. Xiong J, Todorova D, Su NY, Kim J, Lee PJ, et al. (2015) Stemness factor Sall4 is required for DNA damage response in embryonic stem cells.J Cell Biol 208: 513-520.
  27. Nam JW, Rissland OS, Koppstein D, Abreu-Goodger C, Jan CH, et al. (2014) Global analyses of the effect of different cellular contexts on microRNA targeting. Mol Cell 53: 1031-1043.
  28. Xiong J (2014) Key roles of microRNA-22 family in complex organisms inferred from its evolution. Microrna 3: 64-74.
Citation: Xiong J (2015) Multiple Targeting Routes of MicroRNA-22 Inform Cancer Drug Discovery. Gene Technol 4:e114.

Copyright: © 2015 Xiong J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
bellicon